A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Pazopanib (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jan 2018 Status changed from discontinued to withdrawn prior to enrolment.
- 18 Mar 2008 New trial record.